Financial health
- Operating income covered interest expense -2.3× in the latest year.
ASBP Financials Aspire Biopharma Holdings, Inc.
5 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key annual figures
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $6202 | -$24M | -1.9% | -312016.9% | 383.9% | -1865.7% | — | — | $1M |
| 2024 | — | -$1M | — | — | 85.1% | -885.1% | — | — | — |
| 2023 | — | $4M | — | — | -915.0% | 22.3% | — | — | — |
| 2022 | — | $3M | — | — | -33.6% | 1.1% | — | — | — |
| 2021 | — | -$25475 | — | — | 5363.2% | -8.7% | — | — | — |
RevenueNet income
GrossOperatingNet
ROEROA
Free cash flow
CashTotal debt
OperatingInvestingFinancing
Key quarterly figures
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $63104 | -$1M | -47.7% | -4244.1% | -10.8% | -9.4% | — | — | $12M |
| Mar '26 | — | -$3M | — | — | -83.3% | -45.3% | — | — | $6M |
| Dec '25 | — | -$5M | — | — | 73.8% | -358.8% | — | — | $1M |
| Sep '25 | — | -$2M | — | — | 16.1% | -77.0% | — | — | — |
| Jun '25 | — | -$2M | — | — | 20.6% | -200.2% | — | — | — |
| Mar '25 | — | -$16M | — | — | 200.5% | -811.1% | — | — | — |
| Dec '24 | — | -$765710 | — | — | 49.7% | -517.4% | — | — | — |
| Sep '24 | — | -$216269 | — | — | 27.9% | -3.2% | — | — | — |
| Jun '24 | — | -$96923 | — | — | 17.4% | -1.4% | — | — | — |
| Mar '24 | — | -$230970 | — | — | 47.2% | -1.1% | — | — | — |
| Dec '23 | — | -$150912 | — | — | 30.9% | -0.8% | — | — | — |
| Sep '23 | — | -$69258 | — | — | 110.0% | -0.3% | — | — | — |
| Jun '23 | — | $2M | — | — | 692.1% | 8.8% | — | — | — |
| Mar '23 | — | $3M | — | — | -28.0% | 0.9% | — | — | — |
| Dec '22 | — | $2M | — | — | -22.4% | 0.7% | — | — | — |
| Sep '22 | — | $1M | — | — | -11.2% | 0.4% | — | — | — |
| Jun '22 | — | $120693 | — | — | -1.3% | 0.0% | — | — | — |
| Mar '22 | — | -$87826 | — | — | 1.0% | -0.0% | — | — | — |
| Dec '21 | — | -$755 | — | — | 158.9% | -0.3% | — | — | — |
| Sep '21 | — | -$15310 | — | — | -5467.9% | — | — | — | — |
Valuation over time
How the market has priced ASBP against its own fundamentals since 2025-02 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
- The price-to-sales ratio has fallen from 38362.3× (Dec '25) to 1745.8× (Nov '26).
P/S
Frequently asked questions
Is ASBP growing its revenue and profit?
See the revenue and net-income charts above for Aspire Biopharma Holdings, Inc.'s multi-year trend.
How much debt does ASBP have?
As of FY2025, Aspire Biopharma Holdings, Inc. reported — of total debt against $1M of cash; operating income covered interest expense -2.3×.
What is ASBP's profit margin?
In FY2025, gross margin was -1.9%, operating margin -312016.9%, and net margin -394725.1%.
Where does this data come from?
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), split-adjusted; price return — dividends not reinvested · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.